Healthcare Services

Global Typhoid Vi Polysaccharide Vaccine Market Report 2026–2035 Highlighting Expansion Outlook and Forecast Opportunities

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Typhoid Vi Polysaccharide Vaccine Market Projected To Become By 2030 Based On Its 2026 Valuation?

The typhoid vi polysaccharide vaccine market size has experienced rapid growth in recent years. This market is projected to expand from $6.71 billion in 2025 to $7.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 18.1%. The expansion witnessed in the historic period is attributable to the broadening of national immunization schedules, increased public awareness of typhoid prevention, the availability of polysaccharide vaccine formulations, the rise of public vaccination campaigns, and support from global health organizations.

The typhoid Vi polysaccharide vaccine market size is projected to experience substantial expansion in the coming years, anticipated to reach $15.51 billion by 2030, at a compound annual growth rate (CAGR) of 18.3%. This growth during the forecast period can be attributed to a heightened focus on mass immunization in endemic regions, rising investments in vaccine manufacturing capacity, the expansion of adult vaccination programs, a growing emphasis on travel-related immunization, and the increasing adoption of improved vaccine storage technologies. Major trends observed within this period include the rise of government-led immunization programs, increasing demand for pediatric vaccination coverage, a growing focus on preventive healthcare measures, the expansion of public-private vaccine distribution models, and an enhanced emphasis on cold chain optimization.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Typhoid Vi Polysaccharide Vaccine Market?

The increasing occurrence of typhoid is anticipated to boost the expansion of the typhoid Vi polysaccharide vaccine market in the coming years. Typhoid is a potentially fatal infection caused by Salmonella Typhi bacteria, commonly transmitted through tainted food or beverages. Factors contributing to the surge in typhoid prevalence include inadequate sanitation, unsafe water sources, rapid urban development, and heightened exposure to contaminated food and water. The typhoid Vi polysaccharide vaccine market plays a crucial role in addressing this by providing immunizations for adults and children aged 2 years and above, delivering protective immunity against Salmonella enterica serovar Typhi and thereby alleviating the impact of typhoid fever in affected areas. For instance, in August 2024, data released by the UK Health Security Agency indicated an increase in laboratory-confirmed symptomatic enteric fever cases across England, Wales, and Northern Ireland, with S. Typhi reaching 313 cases, S. Paratyphi A reaching 135 cases, and S. Paratyphi B reaching 18 cases. Consequently, the growing prevalence of typhoid is fueling the growth of the typhoid Vi polysaccharide vaccine market.

What Segment Groups Are Identified Within The Typhoid Vi Polysaccharide Vaccine Market?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

How Are Trends Shaping The Direction Of The Typhoid Vi Polysaccharide Vaccine Market?

Leading entities within the typhoid Vi polysaccharide vaccine market are concentrating on reinforcing their standing through tactical investments, including financial collaborations for advanced vaccine delivery platforms, with the goal of expediting breakthroughs and broadening worldwide immunization coverage. These funding alliances for cutting-edge vaccine delivery systems denote joint investment efforts designed to create superior typhoid immunization solutions, specifically formats that are needle-free, stable in varying temperatures, and simple to administer, thereby boosting accessibility, reach, and adherence in areas with limited resources. An example of this is seen in August 2023, when SK Bioscience, a biotechnology firm from South Korea, alongside Vaxxas, an Australian biotech enterprise focused on needle-free vaccine administration, obtained AUD 0.0054 billion (USD 0.00367 billion) in capital from Wellcome, a UK-based philanthropic organization. This funding was allocated for the development of a typhoid conjugate vaccine administered through a needle-free high-density microarray patch (HD-MAP). This particular advancement incorporates a micro-projection patch that removes the necessity for conventional needles, offers thermostability crucial for distribution in regions with underdeveloped infrastructure, and holds the promise of straightforward, discomfort-free administration, ultimately aiming for increased global adoption of typhoid immunization.

Which Companies Hold Significant Positions In The Typhoid Vi Polysaccharide Vaccine Market?

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., Merck & Co. Inc., PT Bio Farma, Bharat Biotech International Limited, Bio-Med Pvt. Ltd., Hualan Biological Engineering Inc., Indian Immunologicals Limited, Serum Institute of India Limited, Biological E Limited, Panacea Biotec Limited, Zydus Lifesciences Limited, Beijing Minhai Biotechnology Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Eubiologics Co. Ltd., Incepta Vaccine Limited, GC Pharma, KM Biologics Inc., Bharat Immunologicals and Biologicals Corporation Limited, Sinovac Biotech Ltd., Bio Farma Indonesia

Read the full typhoid vi polysaccharide vaccine market report here:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Which Regions Are Projected To Dominate The Typhoid Vi Polysaccharide Vaccine Market In The Coming Years?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2025. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Typhoid Vi Polysaccharide Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp

Browse Through More Reports Similar to the Global Typhoid Vi Polysaccharide Vaccine Market 2026, By The Business Research Company

Preventive Vaccines Global Market Report

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Vaccines Global Market Report

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Chickenpox Vaccine Global Market Report

https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795